AstraZeneca Partners with Jacobio to Co-Develop and Commercialize SHP2 Inhibitors for Cancer Treatment
This collaboration could unlock new treatment paradigms for advanced solid tumors by combining SHP2 and MEK inhibitors.
AstraZeneca and Jacobio Pharma announced a collaboration to co-develop and commercialize SHP2 inhibitors for cancer treatment, initiating clinical trials for a combination therapy.
AstraZeneca has entered into a clinical trial collaboration and supply agreement with Jacobio Pharma. The partnership aims to evaluate the combination of Jacobio's SHP2 inhibitor, JAB-3312, and AstraZeneca's MEK inhibitor, selumetinib, for treating patients with advanced solid tumors. This collaboration will explore the potential synergistic effects of targeting both the SHP2 and MEK pathways in cancer therapy.
This collaboration could unlock new treatment paradigms for advanced solid tumors by combining SHP2 and MEK inhibitors. Success in these trials may lead to more effective combination therapies, potentially addressing unmet needs in oncology and strengthening AstraZeneca's position in the precision medicine market.
Where this signal fits in the broader landscape.
AstraZeneca's Datopotamab Deruxtecan Granted Fast Track Designation in US for Metastatic Lung Cancer
AstraZeneca's Enhertu Granted US Priority Review for HER2-Positive Early Breast Cancer Post-Neoadjuvant Treatment
AstraZeneca's Evinova partners with Astellas and BMS to speed up clinical trials using its AI platform.
Health Canada approves Koselugo for adults with neurofibromatosis type 1
https://www.jacobiopharma.com/en/detail/95.html
Read Full SourceGet curated intelligence delivered to your inbox. No spam, unsubscribe anytime.
Sign in to save notes on signals.
Sign In